NCT06792019 - Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

November 16, 2027

Study Completion Date

November 16, 2027

Conditions

Platelet Transfusion Refractoriness

Interventions

BIOLOGICAL

CM313(SC) injection-low dose

Phase IB:CM313(SC) administered at low dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.

BIOLOGICAL

CM313(SC) injection-high dose

Phase IB:CM313(SC) administered at high dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin